Cargando…

N-Truncated Aβ Starting at Position Four—Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer’s Disease

The discussion of whether amyloid plaque Aβ is a valid drug target to fight Alzheimer’s disease (AD) has been a matter of scientific dispute for decades. This question can only be settled by successful clinical trials and the approval of disease-modifying drugs. However, many clinical trials with an...

Descripción completa

Detalles Bibliográficos
Autor principal:	Bayer, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417877/ https://www.ncbi.nlm.nih.gov/pubmed/34489680 http://dx.doi.org/10.3389/fnagi.2021.710579

Ejemplares similares

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease
por: Lopez-Noguerola, Jose S., et al.
Publicado: (2018)

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease
por: Bayer, Thomas A., et al.
Publicado: (2014)

N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody
por: Antonios, Gregory, et al.
Publicado: (2013)

N-truncated Aβ(4–x) peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
por: Wirths, Oliver, et al.
Publicado: (2017)

N-Terminally Truncated and Pyroglutamate-Modified Aβ Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer’s Disease
por: Domingo, Guido, et al.
Publicado: (2021)

Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease
por: Zhou, Yan, et al.
Publicado: (2018)

An Algorithm for Preclinical Diagnosis of Alzheimer's Disease
por: Khan, Tapan K.
Publicado: (2018)

N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
por: Rostagno, Agueda, et al.
Publicado: (2022)

Synaptic Alterations in Mouse Models for Alzheimer Disease—A Special Focus on N-Truncated Abeta 4-42
por: Dietrich, Katharina, et al.
Publicado: (2018)

A Facile Method to Produce N-Terminally Truncated α-Synuclein
por: Thrush, Rebecca J., et al.
Publicado: (2022)

Entorhinal and Transentorhinal Atrophy in Preclinical Alzheimer's Disease
por: Kulason, Sue, et al.
Publicado: (2020)

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
por: Bayer, Thomas A.
Publicado: (2021)

Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2021)

Saccadic Adaptation Is Associated with Starting Eye Position
por: Gremmler, Svenja, et al.
Publicado: (2016)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
por: Insel, Philip S., et al.
Publicado: (2017)

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models
por: Reinert, Jochim, et al.
Publicado: (2016)

Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease
por: Arenaza-Urquijo, Eider M., et al.
Publicado: (2015)

Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
por: Younes, Laurent, et al.
Publicado: (2019)

Truncated Tau caused by intron retention is enriched in Alzheimer’s disease cortex and exhibits altered biochemical properties
por: Ngian, Zhen-Kai, et al.
Publicado: (2022)

The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ
por: Kalimo, Hannu, et al.
Publicado: (2013)

Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer’s Disease
por: Venkatraman, Vijay K., et al.
Publicado: (2020)

Changes of Regional Neural Activity Homogeneity in Preclinical Alzheimer’s Disease: Compensation and Dysfunction
por: Zhang, Zhen, et al.
Publicado: (2021)

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease
por: Menting, Kelly Willemijn, et al.
Publicado: (2014)

N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits
por: Bouter, Yvonne, et al.
Publicado: (2013)

Technical Pitfalls of Signal Truncation in Perfusion MRI of Glioblastoma
por: Wong, Kelvin K., et al.
Publicado: (2016)

Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer’s Disease
por: Fiandaca, Massimo S., et al.
Publicado: (2015)

The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging
por: Zhou, Yanhong, et al.
Publicado: (2016)

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
por: Zhong, Xiaofang, et al.
Publicado: (2019)

Alzheimer's Aβ Peptides with Disease-Associated N-Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu(2+) Coordination
por: Drew, Simon C., et al.
Publicado: (2010)

Subjective Cognitive Decline as a Preclinical Marker for Alzheimer's Disease: The Challenge of Stability Over Time
por: Ávila-Villanueva, Marina, et al.
Publicado: (2017)

Distinct Disruptive Patterns of Default Mode Subnetwork Connectivity Across the Spectrum of Preclinical Alzheimer’s Disease
por: Xue, Chen, et al.
Publicado: (2019)

Transcranial Direct Current Stimulation Alleviates Neurovascular Unit Dysfunction in Mice With Preclinical Alzheimer’s Disease
por: Luo, Yinpei, et al.
Publicado: (2022)

Indolethylamine-N-methyltransferase Polymorphisms: Genetic and Biochemical Approaches for Study of Endogenous N,N,-dimethyltryptamine
por: Dean, Jon G.
Publicado: (2018)

Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer’s Disease
por: Cope, Zackary A., et al.
Publicado: (2022)

Urinary Incontinence and Alzheimer’s Disease: Insights From Patients and Preclinical Models
por: Bartolone, Sarah N., et al.
Publicado: (2021)

The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes
por: Oberstein, Timo Jan, et al.
Publicado: (2021)

Correction: Alzheimer's Aβ Peptides with Disease-Associated N-Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu(2+) Coordination
Publicado: (2014)

Evaluation of Feature Selection for Alzheimer’s Disease Diagnosis
por: Gu, Feng, et al.
Publicado: (2022)

Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD
por: Schindler, Suzanne Elizabeth, et al.
Publicado: (2015)

Effect of acupuncture on neuroinflammation in animal models of Alzheimer’s disease: A preclinical systematic review and meta-analysis
por: Wu, Zhi-Guo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hfbilnpmueeiq69mbbq2vj03m0